

**UNIVERSITA' DI VERONA**

**SCUOLA DI MEDICINA E CHIRURGIA**

**Dottorato di Ricerca in Immunità**

**Inflammation e Cancro**

Coordinatore Prof. Gabriella Constantin

TESI DI DOTTORATO

Tri-Staple vs Ultrasonic Scalpel in Distal Pancreatectomy (TRUDY). A randomized controlled, multicenter, patient blinded, superiority trial

Relatore: Prof. Claudio Bassi

Correlatore: Prof. Roberto Salvia

Dottorando

Dott. Matteo De Pastena

XXXIII ciclo del corso di Dottorato 2017-2020

# Tri-Staple vs Ultrasonic Scalpel in Distal Pancreatectomy (TRUDY). A randomized controlled, multicenter, patient blinded, superiority trial

## Abstract

**Background:** Several systematic reviews have investigated pancreatic stump management to reduce the postoperative pancreatic fistula (POPF) rate. The study aimed to evaluate if the parenchymal transection using the triple-row reinforced stapler decreases the incidence of POPF compared with ultrasonic transection after distal pancreatectomy (DP).

**Methods:** a bicentric, phase 3, patient-blinded, randomized clinical trial was conducted. All patients submitted to elective DP from July 2018 through July 2020 were screened. Exclusion criteria were an extended resection, gastrointestinal resections or anastomoses, and a pancreatic thickness >17 mm measured at the point of parenchymal transection. The experimental group received the Endo GIA Reinforced Reload with Tri-Staple Technology® (TS), while the control group the Harmonic Focus® (US).

**Results:** A total of 152 patients undergoing DP met the inclusion criteria and were randomized. Due to a positive transection margin on frozen section analysis requiring further resection, seven patients were excluded post-randomization. Therefore, the final population comprised 72 patients in the TS arm and 73 patients in the US arm. Overall, 23 patients (16%) developed POPF. There were 19 grade B (14%) and 4 grade C fistulas (2%). The incidence of POPF was similar between groups (TS 12% vs. US 19%,  $p=0.191$ ).

**Conclusion:** the present randomized controlled trial of stapled transection using a PGA-reinforced triple-row stapler versus ultrasonic transection with HARMONIC® energy devices in elective DP demonstrated no significant difference in POPF rates.

## **Introduction**

In the largest series analyzing risk factors for postoperative pancreatic fistula (POPF) following distal pancreatectomy (DP), several perioperative variables were identified (1). Yet, most of the research endeavors have been focused on the pancreatic transection method, a modifiable factor with the potential for improving the fistula rates (2). Several techniques have been proposed, including sharp transection with handsewn closure (using mattress sutures or fish-mouth stitches), stapled transection, transection with energy-based devices (diathermy, ultrasonic devices, with or without ligation of the main pancreatic duct), or even anastomosis of the pancreatic stump to a Roux-en-Y jejunal limb or as a pancreaticogastrostomy (3–7). Furthermore, the use of additional biologic sealants or stump reinforcement with an omental or falciform ligament patch have been investigated with mixed results (8,9). Remarkably, none of these techniques have demonstrated a clear superiority over the others in randomized controlled trials (10,11). Over the last decade, stapler and energy-based devices have been increasingly adopted because of the more frequent use of minimally invasive approaches and because of the easy, fast, and reproducible mechanism of action. Recently a new type of triple-row staplers reinforced with a preloaded bioabsorbable polyglycolic acid (PGA) felt has been marketed, with preliminary data showing a decrease in the incidence and severity of POPF compared with the standard stapler and with ultrasonic devices, provided a pancreatic thickness <17 mm (12–14). In a recent retrospective, propensity-score matched analysis of 184 patients we suggested that the use of a triple-row reinforced stapler was associated with a marked reduction of POPF rates relative to the ultrasonic dissector group (12% versus 40%) (15). Under these premises, we sought to evaluate whether, in elective DP, parenchymal transection using the triple-row reinforced stapler decreases the incidence of POPF compared with ultrasonic transection in the setting of a randomized controlled trial.

## **Methods**

### **Study design and participants**

This study is a bicentric, phase 3, patient-blinded, randomized clinical trial conducted from July 2018 through July 2020 at the Unit of General and Pancreatic Surgery, University of Verona Hospital Trust, Verona, Italy; and the Unit of Pancreatic Surgery, Ospedale Pederzoli, Peschiera del Garda, Italy. The study protocol was approved by the Ethics Committee of the Provinces of Verona and Rovigo (#1664CESC) and registered at ClinicalTrial.gov (NCT03880773). The trial was performed in accordance with the good clinical practice guidelines, the principles of the Declaration of Helsinki, and the Consolidated Standards of Reporting Trials (CONSORT) Guidelines (16). Patients between the ages of 18 and 80 with any indication for elective DP were eligible for inclusion. All eligible patients provided written informed consent at the time of hospital admission. The CONSORT flowchart is reported in Figure 1.

### **Randomization and masking**

The randomization process was as follows: on intraoperative exploration, patients were excluded if an extended DP was needed. This involved a posterior RAMPS for left adrenal/kidney infiltration or a synchronous arterial resection (celiac trunk or hepatic artery) or an associated bowel resection. Synchronous venous resection was not an exclusion criterion. In eligible patients, pancreatic thickness was measured at the point of parenchymal transection via intraoperative ultrasound. Only patients with a parenchymal thickness <17 mm were enrolled in the trial and randomized by telephone in a 1:1 ratio using a computer-generated randomization list kept by independent data managers at the coordinating center (Unit of General and Pancreatic Surgery, University of Verona Hospital Trust) and concealed to the investigators. Patients were blinded to the arm allocation during the postoperative course. The 17-mm cutoff was used to avoid staple closure failure or parenchymal crushing, according to previous evidences (12,17). Post-randomization drop-out occurred in the

instance of positive transection margin on frozen section analysis, requiring an extension of the resection up to total pancreatectomy.

## **Procedures**

DP were performed by specialized pancreatic surgeons who completed the learning curve and had a personal annual caseload exceeding 50 major pancreatic resections. All surgeons were familiar with both of the stump management techniques used in this trial. DP was performed either via laparotomy or minimally invasive approaches (laparoscopic or robot-assisted), with or without spleen preservation (18–20). The level of pancreatic transection at the neck, body, or tail, depended on the nature and the location of the lesion. Stapled transection was performed using an Endo GIA Reinforced Reload with Tri-Staple Technology® (COVIDIEN, North Haven, CT, USA). Either a purple (3 mm) or black (4 mm) cartridge was employed according to the single surgeon's preference. A gradual compression was applied for 2-3 minutes, the stapler was then fired and slowly released after transection. Ultrasonic transection was performed using the Harmonic Focus®+ Shears (open surgery) or the Harmonic Ace®+ Shears (minimally invasive surgery), HARMONIC, Johnson & Johnson Medical, Ethicon, Tokyo, Japan. Ultrasonic technology uses high-frequency mechanical energy that cuts by cavitation fragmentation and simultaneously seals tissues by coaptive coagulation (21). The pancreas was transected at the lowest vibration level, no additional sutures were placed into the pancreatic stump or the main pancreatic duct. In both arms an easy-flow drain was placed in the proximity of pancreatic stump. Postoperative drain management was described elsewhere and was standardized across the participating institutions (22).

## **Outcomes**

The primary endpoint was the incidence of POPF as defined by the International Study Group of Pancreatic Surgery (23). Secondary endpoints were any complications, classified according to the Clavien-Dindo score (24), major complications, defined as Clavien-Dindo grade III or higher,

delayed gastric emptying (DGE) and post-pancreatectomy hemorrhage (PPH), classified according to the International Study Group on Pancreatic Surgery definitions (25,26), postoperative hospital stay (including readmission), and 90-day mortality. Follow-up visits were carried out at 30 and 90 days from the index operation, including cross-sectional imaging (computed tomography or magnetic resonance) serum tumor markers, glycemia, platelet count and physical examination.

### **Statistical Analysis**

The study was designed hypothesizing that stapled transection was superior to ultrasonic transection. The sample size was calculated based on previously published institutional retrospective data reporting a 40% and 12% POPF rates following ultrasonic and stapled transection, respectively (15). Assuming a 20.5% delta in the prospective trial, at a 5% alpha and 80% power (1-beta), the required sample size was 138 patients (69 per arm) according to the continuity corrected Z-Test with unpooled variance. Adjustment for post-randomization drop-out was made expecting a 10% rate of transection margin positivity on frozen section analysis, leading to a total sample size of 152 patients (76 per arm). Demographic and clinical characteristics were age, gender, American Society of Anesthesiologists (ASA) score, body mass index (BMI, kg/m<sup>2</sup>) categorized based on WHO classification (27), diabetes mellitus, age-adjusted Charlson comorbidity index score (28), chronic steroid therapy, neoadjuvant chemotherapy. Surgical variables included operative approach, conversion from minimally invasive to open approach, splenectomy, pancreatic gland thickness measured by intraoperative ultrasound at the point of transection, transection level categorized into gastroduodenal artery level, pancreatic neck, and left border of the aorta or more distal, vascular venous resection, intraoperative blood loss (mL), and operating time (minutes). In the stapled transection arm, the compression ratio (defined as the pancreas thickness divided by the closed length of the stapler), and the height difference (defined as the difference between the pancreatic thickness and the closed length of the stapler) were calculated (12,29). The values of closed length were defined per the manufacturer specifications.

Continuous variables were expressed as means with standard deviation or medians with interquartile range (IQR) and compared using t-test or Mann-Whitney test, as appropriate. Categorical variables were expressed as absolute numbers and percentages and compared using chi-square test or Fisher's exact test. All tests were two-tailed. Binary logistic regression analysis was performed to investigate factors associated with POPF. Factors with a p-value <0.1 on univariable screening were entered in the model. Data are presented with odds ratios and 95% confidence intervals. A p-value <0.05 was considered statistically significant. Data were analyzed using the Statistical Package for the Social Sciences 25.0 for Windows (SPSS, Inc, Chicago, IL, USA).

## **Results**

### *General characteristics*

A total of 152 patients undergoing DP met the inclusion criteria and were randomized (Figure 2). Due to a positive transection margin on frozen section analysis requiring further resection, seven patients were excluded post-randomization. Therefore, the final population comprised 72 patients in the stapled transection arm and 73 patients in the ultrasonic transection arm. The baseline characteristics per randomization arm are outlined in Table 1. The median pancreatic thickness measured intraoperatively at the transection level was 12 mm in both groups.

### *Primary endpoint*

Overall, 23 patients (16%) developed POPF (Table 2). There were 19 grade B (14%) and 4 grade C fistulas (2%). The incidence of POPF was similar between groups (12% in stapled transection versus 19% in ultrasonic dissection, p=0.191). Biochemical leak (BL) occurred in 42 patients (29%), 21 patients in each arm (p=0.552).

### *Secondary endpoints*

Table 2 shows the postoperative outcomes. In all, 57 patients (39%) had any complication, without differences between groups (35% in stapled transection versus 44% in ultrasonic transection,  $p=0.170$ ). There was an increased incidence of abdominal collections in the ultrasonic dissection group (32% versus 14%,  $p=0.009$ ). Five patients (3%) underwent reoperation, mostly for a hemorrhage (three of five patients). There was one postoperative death in the ultrasonic dissection group. This patient died on postoperative day four of an aortic dissection, that was confirmed on autopsy. The median length of stay was similar between groups (8 days,  $p=0.880$ ).

Sub-analysis of risk factors for POPF is shown in Table 3. POPF was associated with a higher median BMI, pancreas transection level, and intraoperative blood transfusion. In the stapled transection group, the compression rate and the height difference were not correlated with POPF ( $p=0.362$  and  $p=0.979$ , respectively). Intraoperative blood transfusion was the only independent risk factors for POPF (OR 4.8, 95% CI 1.2-20,  $p=0.032$ ) on logistic regression analysis (Table 4).

## **Discussion**

The present randomized clinical trial of stapled versus ultrasonic transection in DP demonstrated no significant difference in POPF rates. Analysis of secondary outcomes revealed a greater incidence of abdominal collections in the ultrasonic dissection arm. POPF therefore remains a clinically relevant and unsolved issue for patients undergoing elective DP, with a formation process likely independent on the surgical technique adopted for resection and closure of the pancreatic remnant. Our findings indeed resonate with previously published randomized controlled trials, that did not identify an optimal transection method able to decrease POPF in DP (30).

To the best of our knowledge, this is the first randomized trial of a triple-row stapler reinforced with a preloaded PGA felt. Previous studies had already shown that wrapping the pancreatic stump with a PGA mesh decreased the rate of POPF (31,32), and triple-row stapler had been associated with less POPF compared with the double-row staplers (33). The Endo GIA Reinforced Reload with Tri-Staple Technology® has been available at the authors' institution since its introduction into the market and

has been employed at the surgeon's discretion for parenchymal transection in DP. A retrospective propensity-matched analysis comparing surgical outcomes with ultrasonic dissection (HARMONIC® Focus or Ace) suggested a significantly decreased rate of POPF in the reinforced Tri-Staple group (12% versus 40%), constituting the backbone for the present trial. As suggested by earlier studies, patients with a parenchymal thickness > 17 mm were excluded because of a very high incidence of POPF that was independent on the type of cartridge (12). In patients who were randomized to stapled transection we gradually compressed the pancreas with the stapler for about 2-3 minutes, then divided the parenchyma and released the device slowly. This has been shown to help avoiding the development of POPF (34). Nonetheless, the choice of the stapler cartridge was left at the single surgeon's discretion. While cartridges with closed length <15 mm (i.e. purple) have been shown to be particularly suitable for thin pancreata (<12 mm), in thicker glands a longer staple height has been recommended (i.e. black) although no particular cartridge has proven to outperform the others.

In the ultrasonic dissection arm, the pancreas was transected and simultaneously sealed by coaptive coagulation at the lowest vibration level. Several experimental studies proved that the lateral thermal spread is limited to 0-2 mm beyond the tissue grasped within the forceps of the device (35). The decreased propensity for collateral thermal damage is an important putative advantage of the Harmonic scalpel, particularly when compared with other energy devices such as monopolar and bipolar diathermy, which are commonly used for pancreatic transection in DP (30). However, a correlation between ultrasonic transection and POPF healing has been suggested by our group, in that ultrasonic transection resulted independently associated with a slower fistula healing (36). Whether this depends on thermal damage has to be fully elucidated.

Analysis of factors associated with POPF suggest that BMI and the anatomic transection level play an integral role to the process. BMI is indeed a surrogate of fatty infiltration, that has been shown to correlate with a complicated clinical course (26,33,34). Even the transection level has been widely reported as a predictor of POPF, because the pancreas thickness is anatomically different at the

gastroduodenal artery level, at the neck, or in the body and tail (8,11). Nonetheless, only intraoperative blood transfusion was an independent risk factor on multivariable analysis. This is in accordance with a recent systematic review and meta-analysis and might be a surrogate parameter for pancreatic stump ischemia (38). Taken together, these results emphasize the need for perioperative composite scores to predict high-risk scenarios and help establishing individualized prevention and mitigation strategies. While these tools have been derived and successfully validated in pancreatoduodenectomy (39), previous efforts in large, multi-institutional DP series have proven elusive (40).

The study has some limitations. First, sub-analysis of stapler cartridges was not done. The liberal use of purple or black cartridge with PGA reinforcement possibly introduced a bias. However, the compression rate and the height difference were not associated with POPF. Another limitation could be the difference in the anatomic point of parenchymal transection, that was indeed associated with POPF. Nonetheless, the point of transection was dictated by the underlying pathology, with parenchyma-sparing procedures being favored in the context of benign to low-grade neoplasms. Indeed, this parameter did not result to be a risk factor at the adjusted analysis.

## **Conclusion**

The present randomized controlled trial of stapled transection using a PGA-reinforced triple-row stapler versus ultrasonic transection with HARMONIC® energy devices in elective DP demonstrated no significant difference in POPF rates and no substantial impact on other secondary endpoints. The optimal technique for the management of pancreatic stump in resection of the left pancreas remains unclear.

## References

1. Kleeff J, Diener MK, Z'graggen K, Hinz U, Wagner M, Bachmann J, et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. *Ann Surg*. 2007 Apr;245(4):573–82.
2. Knaebel HP, Diener MK, Wente MN, Büchler MW, Seiler CM. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. *Br J Surg*. 2005 May;92(5):539–46.
3. Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. *Lancet Lond Engl*. 2011 Apr 30;377(9776):1514–22.
4. Bilimoria MM, Cormier JN, Mun Y, Lee JE, Evans DB, Pisters PWT. Pancreatic leak after left pancreatectomy is reduced following main pancreatic duct ligation. *Br J Surg*. 2003 Feb;90(2):190–6.
5. Sheehan MK, Beck K, Creech S, Pickleman J, Aranha GV. Distal pancreatectomy: does the method of closure influence fistula formation? *Am Surg*. 2002 Mar;68(3):264–7; discussion 267–268.
6. Suzuki Y, Fujino Y, Tanioka Y, Hori Y, Ueda T, Takeyama Y, et al. Randomized clinical trial of ultrasonic dissector or conventional division in distal pancreatectomy for non-fibrotic pancreas. *Br J Surg*. 1999 May;86(5):608–11.
7. Kawai M, Hirono S, Okada K-I, Sho M, Nakajima Y, Eguchi H, et al. Randomized Controlled Trial of Pancreaticojejunostomy versus Stapler Closure of the Pancreatic Stump During Distal Pancreatectomy to Reduce Pancreatic Fistula. *Ann Surg*. 2016;264(1):180–7.
8. Hassenpflug M, Hinz U, Strobel O, Volpert J, Knebel P, Diener MK, et al. Teres Ligament Patch Reduces Relevant Morbidity After Distal Pancreatectomy (the DISCOVER Randomized Controlled Trial). *Ann Surg*. 2016 Nov;264(5):723–30.
9. Hüttner FJ, Mihaljevic AL, Hackert T, Ulrich A, Büchler MW, Diener MK. Effectiveness of Tachosil(®) in the prevention of postoperative pancreatic fistula after distal pancreatectomy: a systematic review and meta-analysis. *Langenbecks Arch Surg*. 2016 Mar;401(2):151–9.
10. Zhang H, Zhu F, Shen M, Tian R, Shi CJ, Wang X, et al. Systematic review and meta-analysis comparing three techniques for pancreatic remnant closure following distal pancreatectomy. *Br J Surg*. 2015 Jan;102(1):4–15.
11. Ban D, Shimada K, Konishi M, Saiura A, Hashimoto M, Uesaka K. Stapler and nonstapler closure of the pancreatic remnant after distal pancreatectomy: multicenter retrospective analysis of 388 patients. *World J Surg*. 2012 Aug;36(8):1866–73.
12. Kim H, Jang J-Y, Son D, Lee S, Han Y, Shin YC, et al. Optimal stapler cartridge selection according to the thickness of the pancreas in distal pancreatectomy. *Medicine (Baltimore)*. 2016 Aug;95(35):e4441.
13. Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Yamaki S, Kosaka H, et al. Comparison of surgical outcomes of three different stump closure techniques during distal pancreatectomy. *Pancreatol Off J Int Assoc Pancreatol IAP Al*. 2017 Jun;17(3):497–503.
14. Yamashita Y-I, Tsujita E, Chikamoto A, Imai K, Kaida T, Yamao T, et al. Linear Stapling Device with Pre-attached Bioabsorbable Polyglycolic Acid Felt Reduces Postoperative Pancreatic Fistula After Distal Pancreatectomy. *Anticancer Res*. 2017;37(4):1865–8.
15. Pulvirenti A, Landoni L, Borin A, De Pastena M, Fontana M, Pea A, et al. Reinforced stapler versus ultrasonic dissector for pancreatic transection and stump closure for distal pancreatectomy: A propensity matched analysis. *Surgery*. 2019 Apr 8;
16. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010 Mar 23;340:c332.
17. Kang MK, Kim H, Byun Y, Han Y, Choi YJ, Kang JS, et al. Optimal stapler cartridge selection to reduce post-operative pancreatic fistula according to the pancreatic characteristics in

stapler closure distal pancreatectomy. *HPB*. 2020 Oct 2;

18. Melotti G, Butturini G, Piccoli M, Casetti L, Bassi C, Mullineris B, et al. Laparoscopic distal pancreatectomy: results on a consecutive series of 58 patients. *Ann Surg*. 2007 Jul;246(1):77–82.
19. Esposito A, Casetti L, De Pastena M, Ramera M, Montagnini G, Landoni L, et al. Robotic spleen-preserving distal pancreatectomy: the Verona experience. *Updat Surg*. 2020 Mar 11;
20. De Pastena M, Esposito A, Paiella S, Surci N, Montagnini G, Marchegiani G, et al. Cost-effectiveness and quality of life analysis of laparoscopic and robotic distal pancreatectomy: a propensity score-matched study. *Surg Endosc*. 2020 Apr 2;
21. Salvia R, Malleo G, Marchegiani G, Butturini G, Esposito A, Bassi C. Pancreaticoduodenectomy with harmonic focus curved shears for cancer. *Dig Surg*. 2014;31(4–5):249–54.
22. Bassi C, Molinari E, Malleo G, Crippa S, Butturini G, Salvia R, et al. Early Versus Late Drain Removal After Standard Pancreatic Resections: Results of a Prospective Randomized Trial. *Ann Surg*. 2010 Aug;252(2):207.
23. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. *Surgery*. 2017;161(3):584–91.
24. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. *Ann Surg*. 2004 Aug;240(2):205–13.
25. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery*. 2007 Nov;142(5):761–8.
26. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. *Surgery*. 2007 Jul;142(1):20–5.
27. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Apr 15]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK541070/>
28. Chang C-M, Yin W-Y, Wei C-K, Wu C-C, Su Y-C, Yu C-H, et al. Adjusted Age-Adjusted Charlson Comorbidity Index Score as a Risk Measure of Perioperative Mortality before Cancer Surgery. *PloS One*. 2016;11(2):e0148076.
29. Nishikawa M, Yamamoto J, Hoshikawa M, Einama T, Noro T, Aosasa S, et al. Stapler sizes optimized for pancreatic thickness can reduce pancreatic fistula incidence after distal pancreatectomy. *Surg Today*. 2020 Jun;50(6):623–31.
30. Miao Y, Lu Z, Yeo CJ, Vollmer CM, Fernandez-Del Castillo C, Ghaneh P, et al. Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery*. 2020;168(1):72–84.
31. Park JS, Lee D-H, Jang J-Y, Han Y, Yoon DS, Kim JK, et al. Use of TachoSil(®) patches to prevent pancreatic leaks after distal pancreatectomy: a prospective, multicenter, randomized controlled study. *J Hepato-Biliary-Pancreat Sci*. 2016 Feb;23(2):110–7.
32. Malleo G, Marchegiani G, Borin A, Capelli P, Accordini F, Butturini G, et al. Observational study of the incidence of pancreatic and extrapancreatic malignancies during surveillance of patients with branch-duct intraductal papillary mucinous neoplasm. *Ann Surg*. 2015 May;261(5):984–90.
33. Jang J-Y, Shin YC, Han Y, Park JS, Han H-S, Hwang HK, et al. Effect of Polyglycolic Acid Mesh for Prevention of Pancreatic Fistula Following Distal Pancreatectomy: A Randomized Clinical Trial. *JAMA Surg*. 2017 01;152(2):150–5.
34. Asbun HJ, Van Hilst J, Tsamalaidze L, Kawaguchi Y, Sanford D, Pereira L, et al. Technique and audited outcomes of laparoscopic distal pancreatectomy combining the clockwise approach,

- progressive stepwise compression technique, and staple line reinforcement. *Surg Endosc.* 2020;34(1):231–9.
35. Sutton PA, Awad S, Perkins AC, Lobo DN. Comparison of lateral thermal spread using monopolar and bipolar diathermy, the Harmonic Scalpel and the Ligasure. *Br J Surg.* 2010 Mar;97(3):428–33.
36. Andrianello S, Marchegiani G, Bannone E, Vacca P, Esposito A, Casetti L, et al. Predictors of pancreatic fistula healing time after distal pancreatectomy. *J Hepato-Biliary-Pancreat Sci.* 2020 Oct 15;
37. Mathur A, Pitt HA, Marine M, Saxena R, Schmidt CM, Howard TJ, et al. Fatty pancreas: a factor in postoperative pancreatic fistula. *Ann Surg.* 2007 Dec;246(6):1058–64.
38. Peng Y-P, Zhu X-L, Yin L-D, Zhu Y, Wei J-S, Wu J-L, et al. Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis. *Sci Rep [Internet].* 2017 Mar 15 [cited 2020 Dec 9];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428241/>
39. Trudeau MT, Casciani F, Ecker BL, Maggino L, Seykora TF, Puri P, et al. The Fistula Risk Score Catalog: Toward Precision Medicine for Pancreatic Fistula After Pancreatoduodenectomy. *Ann Surg.* 2020 Jun 11;
40. Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, et al. Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group. *Ann Surg.* 2019;269(1):143–9.

## Tables and Figures

Figure 1. TRUDY CONSORT diagram




Table 1. *Demographic, Intraoperative, and Pathological data*

<b>Study Population N° = 145</b>			
	<b>Total n° (%)</b>	<b>Stapler transection 72 (50%)</b>	<b>Ultrasonic transection 73 (50%)</b>
Age (years, IQR)	60 [50-70]	62 [50-70]	60 [50-69]
Gender (Female)	87 (60%)	48 (67%)	39 (53%)
BMI (Kg/m <sup>2</sup> , IQR)	25 [22-27]	24 [21-27]	25 [22-28]
Diabetes	24 (17%)	13 (18%)	11 (15%)
ASA score ≥ III	18 (12%)	8 (11%)	10 (14%)
Charlson Age >4	48 (33%)	25 (35%)	23 (32%)
Neoadjuvant therapy	31 (21%)	15 (21%)	16 (22%)
Minimally invasive	59 (41%)	29 (40%)	30 (41%)
Conversion <sup>#</sup>	2 (3%)	0 (0%)	2 (7%)
Spleen preserving	14 (17%)	10 (14%)	14 (19%)
Vascular resection	4 (3%)	0 (0%)	4 (6%)
Transection level			
Pancreatic neck	104 (72%)	50 (69%)	54 (74%)
GDA level	3 (2%)	3 (4%)	0 (0%)
Left aortic border	38 (26%)	19 (26%)	19 (26%)
IOUS thickness (mm, IQR)	12 [10-14]	12 [10-14]	12 [10-15]
Duration of Surgery (minutes, IQR)	251 [201-334]	246 [201-321]	257 [202-335]
EBL (cc, IQR)	100 [50-300]	100 [100-300]	150 [50-300]
Blood transfusion	11 (8%)	4 (6%)	7 (10%)
Pathology, No. (%)			
PDAC	54 (37%)	32 (44%)	22 (30%)

pNET	39 (27%)	17 (24%)	22 (30%)
IPMN	8 (6%)	4 (6%)	4 (6%)
MCN/SCN	30 (20%)	16 (22%)	14 (19%)
SPT	6 (4%)	2 (3%)	4 (6%)
Other	8 (6%)	1 (1%)	7 (9%)

---

# Referred to minimally-invasive procedures

BMI: body mass index; ASA: American society of Anesthesiology; GDA: gastroduodenal artery; IOUS: intraoperative ultrasound; EBL: estimated blood loss; PDAC: pancreatic ductal adenocarcinoma; pNET: pancreatic neuroendocrine tumor; IPMN: intraductal papillary mucinous neoplasm; MCN: mucinous cystic neoplasm; SCN: serous cystic neoplasm; SPT: solid pseudopapillary tumor

---

Table 2. *Postoperative outcomes*

<b>Study Population N° = 145</b>				
	<b>Total n° (%)</b>	<b>Stapler transection 72 (50%)</b>	<b>Ultrasonic transection 73 (50%)</b>	<b>p-value</b>
Any complication	57 (39%)	25 (35%)	32 (44%)	0.170
POPF	23 (16%)	9 (12%)	14 (19%)	0.191
Grade B	19 (14%)	8 (12%)	11 (16%)	
Grade C	4 (2%)	1 (1%)	3 (4%)	
Biochemical leak	42 (29%)	21 (29%)	21 (29%)	0.552
Abdominal collection	33 (23%)	10 (14%)	23 (32%)	<b>0.009</b>
DGE	4 (3%)	3 (4%)	1 (1%)	0.305
PPH	11 (8%)	3 (4%)	8 (11%)	0.109
ICU Admission	17 (12%)	7 (9%)	10 (13%)	0.314
Clavien-Dindo $\geq 3$	19 (13%)	6 (8%)	13 (18%)	0.074
Length of Stay (days, IQR)	8 [6-13]	8 [6-13]	8 [6-12]	0.880
Reoperation	5 (3%)	2 (3%)	3 (4%)	0.507
Readmission	14 (10%)	4 (6%)	10 (14%)	0.083
Mortality	1 (1%)	0 (0%)	1 (1%)	0.500

POPF: postoperative pancreatic fistula; DGE: delayed gastric empty; PPH: Post pancreatectomy hemorrhage; ICU: intensive care unit.

Table 3. *Univariable analysis of factors associated with POPF*

Study Population N° = 145			
	POPF 23 (16%)	No POPF 122 (84%)	p-value
Age (years, IQR)	62 [55-71]	60 [50-69]	0.564
Sex (Female)	11 (48%)	76 (62%)	0.143
BMI (Kg/m <sup>2</sup> , IQR)	26 [25-29]	24 [21-27]	<b>0.013</b>
Diabetes	2 (9%)	22 (18%)	0.218
ASA score ≥ III	3 (13%)	15 (12%)	0.573
Charlson Age >4	8 (35%)	40 (33%)	0.514
Neoadjuvant therapy	5 (22%)	26 (21%)	0.577
Minimally invasive	12 (52%)	47 (39%)	0.161
Spleen preserving	4 (17%)	20 (16%)	0.555
Vascular resection	1 (4%)	3 (3%)	0.503
Transection level			<b>0.040</b>
Pancreatic neck	14 (13%)	90 (87%)	
GDA level	2 (67%)	1 (33%)	
Left aortic border	7 (18%)	31 (82%)	
IOUS thickness (mm, IQR)	13 [11-15]	12 [10-14]	0.307
Compression Rate <sup>#</sup> (mm, SD)	3,5 ± 0,5	3,4 ± 0,6	0.362
Height Difference <sup>#</sup> (mm, SD)	8,3 ± 1,8	8,3 ± 2,2	0.979
Duration of Surgery (minutes, IQR)	293 [216-378]	246 [201-321]	0.126
EBL (cc, IQR)	200 [75-300]	100 [50-300]	0.399
Blood transfusion	5 (22%)	6 (5%)	<b>0.016</b>
Pathology PDAC	10 (19%)	13 (14%)	0.326

---

# related only to the TS group patients

BMI: body mass index; ASA: American society of Anesthesiology; GDA: gastroduodenal artery; IOUS: intraoperative ultrasound; EBL: estimated blood loss; PDAC: pancreatic ductal adenocarcinoma

---

Table 4. *Multivariable analysis of factors associated with POPF*

<b>Study Population N° = 145</b>			
	<b>POPF</b>	<b>P value</b>	<b>OR (CI 95%)</b>
BMI (Kg/m <sup>2</sup> )			
<24,9 Kg/m <sup>2</sup>	7 (10%)	1	\
25-29,9 Kg/m <sup>2</sup>	11 (20%)	0.209	1.9 (0.6 - 5.8)
>30 Kg/m <sup>2</sup>	5 (29%)	0.924	1 (0.4 – 2.3)
Transection level			
Pancreatic neck	14 (13%)	1	\
GDA level	2 (67%)	0.357	1.4 (0.6 – 3.4)
Left aortic border	7 (18%)	0.114	0.2 (0.3 – 1.5)
Blood transfusion	5 (46%)	<b>0.032</b>	4.8 (1.2 - 20)

BMI: body mass index; GDA: gastroduodenal artery; POPF: postoperative pancreatic fistula.

